Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jun;10(4):240-9.
doi: 10.2174/138920209788488553.

An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings

Andrea Tinelli  1 , Daniele Vergara, Roberta Martignago, Giuseppe Leo, Maurizio Pisanò, Antonio Malvasi
Affiliations

An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings

Andrea Tinelli et al. Curr Genomics. 2009 Jun.

Abstract

Among the gynaecological malignancies, ovarian cancer is one of the neoplastic forms with the poorest prognosis and with the bad overall and disease-free survival rates than other gynaecological cancers. Ovarian tumors can be classified on the basis of the cells of origin in epithelial, stromal and germ cell tumors. Epithelial ovarian tumors display great histological heterogeneity and can be further subdivided into benign, intermediate or borderline, and invasive tumors. Several studies on ovarian tumors, have focused on the identification of both diagnostic and prognostic markers for applications in clinical practice. High-throughput technologies have accelerated the process of biomolecular study and genomic discovery; unfortunately, validity of these should be still demonstrated by extensive researches on sensibility and sensitivity of ovarian cancer novel biomarkers, determining whether gene profiling and proteomics could help differentiate between patients with metastatic ovarian cancer and primary ovarian carcinomas, and their potential impact on management. Therefore, considerable interest lies in identifying molecular and protein biomarkers and indicators to guide treatment decisions and clinical follow up. In this review, the current state of knowledge about the genoproteomic and potential clinical value of gene expression profiling in ovarian cancer and ovarian borderline tumors is discussed, focusing on three main areas: distinguishing normal ovarian tissue from ovarian cancers and borderline tumors, identifying different genotypes of ovarian tissue and identifying proteins linked to cancer or tumor development. By these targets, authors focus on the use of novel molecules, developed on the proteomics and genomics researches, as potential protein biomarkers in the management of ovarian cancer or borderline tumor, overlooking on current state of the art and on future perspectives of researches.

Keywords: Ovarian cancer; borderline ovarian tumors; genomics; markers; oncogenes.; proteomics.

PubMed Disclaimer

References

    1. Gerd HC, Rikke C, Gerda E, Krüger KS. Survival of ovarian cancer patients in Denmark: Excess mortality risk analysis of five-year relative survival in the period 1978-2002. Acta Obstet. Gynecol. Scand. 2008;87(12):1353–1360. - PubMed
    1. Modugno F, Ness RB, Wheeler JE. Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. Ann. Epidemiol. 2001;11:568–574. - PubMed
    1. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquis M, Winget M, Yasui Y. Phases of Biomarker Development for Early Detection of Cancer. J. Natl. Cancer Inst. 2001;93(14):1054–1061. - PubMed
    1. Ludwig JA, Weisten JN. Biomarkers in Cancer Staging, Prognosis and Treatment Selection. Nat. Rev. Cancer. 2005;5(11):845–856. - PubMed
    1. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X, Hamilton TC. Focus on epithelial ovarian cancer. Cancer Cell. 2004;5:19–24. - PubMed